

# Human Native and Reconstructed Skin Preparations for In Vitro Penetration and Permeation Studies

# 10

Ulrich F. Schaefer, D. Selzer, S. Hansen,  
and Claus-Michael Lehr

## Contents

10.1	<b>Introduction</b> .....	186	10.3.7	Duration of Exposure and Sampling Period .....	195
10.1.1	Needs for In Vitro Skin Absorption Studies .....	186	10.3.8	Quantification Methods .....	196
10.1.2	Rate Determining Processes Involved in Skin Absorption.....	186	10.3.9	Influence of Thickness of Skin Preparation .....	196
10.2	<b>In Vitro Barriers for Skin Absorption Studies</b> .....	187	10.3.10	Number of Experiments/Replicates.....	196
10.2.1	Excised Human Skin .....	187	10.3.11	Segmentation of Skin in Different Skin Layers .....	196
10.2.2	Animal Skin.....	190	10.4	<b>Results Obtained from Permeation Studies</b> .....	197
10.2.3	Bioengineered Skin .....	190	10.4.1	Infinite Dosing Studies .....	198
10.2.4	Artificial Skin Surrogates .....	191	10.4.2	Finite Dosing Studies .....	198
10.3	<b>In Vitro Experimental Setups for Skin Absorption Studies</b> .....	192	10.5	<b>Results Obtained from Penetration Studies</b> .....	198
10.3.1	Finite Versus Infinite Dosing .....	192	<b>Conclusion</b> .....		199
10.3.2	Open Versus Occluded Dosing .....	193	<b>References</b> .....		199
10.3.3	Diffusion Cells .....	193			
10.3.4	Barrier Integrity Check .....	194			
10.3.5	Temperature .....	195			
10.3.6	Selection of Receptor Fluid .....	195			

U.F. Schaefer (✉) • D. Selzer  
Biopharmaceutics and Pharmaceutical Technology,  
Saarland University, Campus A 4.1, D-66123  
Saarbruecken, Germany  
e-mail: [ufs@mx.uni-saarland.de](mailto:ufs@mx.uni-saarland.de)

S. Hansen • C.-M. Lehr (✉)  
Biopharmaceutics and Pharmaceutical Technology,  
Saarland University, Campus A 4.1, D-66123  
Saarbruecken, Germany

Department of Drug Delivery, Helmholtz-Institute  
for Pharmaceutical Research Saarland (HIPS),  
Helmholtz Center for Infection Research (HZI),  
Campus E 8.1, D-66123 Saarbruecken, Germany  
e-mail: [Claus-Michael.Lehr@helmholtz-hzi.de](mailto:Claus-Michael.Lehr@helmholtz-hzi.de)

## Abbreviations

C <sub>ss</sub>	Saturation concentration of solute in the vehicle
C <sub>v</sub>	Concentration in the vehicle
EC	European Commission
ECETOC	European Centre for Ecotoxicology and Toxicology of Chemicals
EDETOX	Evaluations and predictions of dermal absorption of toxic chemicals
EEC	European Economic Community
EFSA	European Food Safety Authority
HaCaT	Human adult low calcium high temperature keratinocytes

HPLC	High-performance liquid chromatography
$J_{\text{peak}}$	Peak flux
$J_{\text{ss}}$	Steady state flux
$J_{\text{ss(max)}}$	Maximum flux
LC	Liquid chromatography
$K^P$	Apparent permeability coefficient
MS	Mass spectrometry
NAFTA	North American Free Trade Agreement
REACH	Registration, Evaluation, Authorisation and Restriction of Chemicals
SC	Stratum corneum
SCCNFP	Scientific Committee on Cosmetic Products and Non-Food Products
SCCS	Scientific Committee on Consumer Safety
TEWL	Transepidermal water loss
$t_{\text{lag}}$	Lag-time
USEPA	US Environmental Protection Agency
WHO	World Health Organisation

## 10.1 Introduction

### 10.1.1 Needs for In Vitro Skin Absorption Studies

As an easy accessible organ our skin is used since a long time for the application of cosmetics and furthermore also for the application of drugs. Primarily, however, the skin is actually a protective organ hindering the invasion of foreign substances from the environment to our body and to maintain homeostasis. Therefore, different reasons exist to monitor the fate of compounds in contact with the skin, for example, to assure that no absorption occurs (cosmetics or hazardous substances) or vice versa to demonstrate that skin absorption does takes place, indeed (drug delivery). While the motivation and scope for skin absorption studies might be different, the same experimental setups can be used to gather the desired information. In contrast to clinical studies or animal experiments, in vitro skin absorption studies allow the screening of different formulations, without any ethical restrictions, which is a particular problem for cosmetics where animal experiments have been banned (EEC 1976; Rossignol 2005). Besides these advantages, the

major drawback of in vitro skin absorption studies is the absence of peripheral blood flow which cannot be simulated completely. Furthermore, concerning risk assessment the acceptance of in vitro skin absorption data by the authorities are different. In the European Union, dermal absorption data for many pesticides has been estimated by in vitro experiments (EC 2003a, b; EFSA 2012). In contrast, NAFTA countries (the USA, Canada, and Mexico (NAFTA 2009)) do not accept in vitro skin absorption data alone for risk assessment. However, most of the skin absorption data published in the field of cosmetic and pharmaceutical sciences is based on in vitro skin absorption studies.

### 10.1.2 Rate Determining Processes Involved in Skin Absorption

In general, skin invasion is predominantly governed by the stratum corneum, which is accepted as the main barrier of the skin. Passive diffusion according to Fick's law is considered the rate determining kinetic process for skin absorption. Modulation of this diffusion process therefore allows controlling skin invasion.

#### 10.1.2.1 Pathways Through the Healthy Skin

While for healthy skin the barrier function is typically located in the stratum corneum (SC), the bottleneck for invasion of very lipophilic substances shifts down to the junction of SC and viable epidermis due to their reduced solubility in the aqueous epidermis layers (Moghimi et al. 1999). This different behavior has to be regarded when in vitro skin absorption studies are carried out.

Based on the anatomical structure of the skin, two basically different pathways for substance invasion are to be considered:

1. Diffusion across the intact SC, the outermost layer of the skin.
2. Invasion via skin appendages such as hair follicles or glands.

Normally the route through the intact SC accounts for the main pathway of skin absorp-

tion, especially if small and dissolved molecules are concerned. However, for nanoparticles or submicron-sized drug delivery systems, for example, liposomes and nanoparticles, the appendageal pathway may be predominant (Lademann et al. 2006, 2007; Patzelt et al. 2011). An additional mechanical rubbing, e.g., a massage, will improve the appendageal delivery. Moreover, for healthy skin it is reported that nanoparticles >10 nm are unlikely to overcome the SC barrier (Prow et al. 2011).

Governed by the anatomical structure of the intact SC the following absorption pathways are feasible: the intercellular route and the transcellular route. The intercellular route is associated with the lipid bilayer structures in between the corneocytes and is considered to be the predominating invasion route, particularly if steady state conditions are assumed. Due to the liquid crystalline structures of the lipid matrix surrounding the corneocytes, the intercellular route provides hydrophilic as well as lipophilic domains offering the possibility that both lipophilic and hydrophilic entities diffuse via this pathway. Although the intercellular route is very tortuous and therefore much longer, the diffusion is relatively fast in this region due to the enhanced diffusion coefficient in comparison to the corneocytes. Furthermore, this pathway can easily be modulated by penetration enhancers. The transcellular route is normally regarded negligible because diffusion in the solid corneocytes is low and the necessity to partition several times between the lipidic bilayers and the more hydrophilic corneocytes. Both phenomena result in a reduced absorption with the exception if penetration enhancers are used which increase the permeability of the corneocytes, e.g., by application of urea due to keratolytic actions (Williams and Barry 2012).

As a result of the various possibilities for substance invasion through and into the SC in vitro skin absorption experiments must take into account these different pathways.

### 10.1.2.2 Pathways Through the Diseased Skin

In diseased skin the barrier function is reduced because of structural changes in the SC. For

example, the lipid bilayer structure is partly lost or the number of SC layers may be reduced. Therefore, from studies with healthy skin only limited conclusions can be drawn for diseased skin. However, there are nowadays also in vitro models available to mimic the situation of diseased skin (see Sect. 10.2.1.5).

---


## 10.2 In Vitro Barriers for Skin Absorption Studies

### 10.2.1 Excised Human Skin

Excised human skin from surgery is the best available in vitro model for skin absorption studies, it is therefore considered as the gold standard. When using skin from surgery, care has to be taken during transport and preparation. In any case, transport and preparation conditions have to be standardized and must be considered when interpreting the results. The following fundamental points have to be noted. As several cycles of freezing and thawing influence the absorption behavior of the skin, freeze-thaw cycles should be avoided at all cost. Thus, transport at reduced temperature, e.g., on ice packs with no direct contact to the skin, is appropriate. During transport and skin preparation, care must be taken to prevent the skin surface from contamination by lipids originating from the subcutaneous fatty tissue which will change the permeability characteristics of the SC (Wertz 1996). It has been shown that the storage period in a freezer (−20 to −26 °C) should be limited to 6 months (Swarbrick et al. 1982; Harrison et al. 1984; Hawkins and Reifenrath 1984; Bronaugh et al. 1986; Schaefer and Loth 1996) as otherwise the barrier function may be affected. Furthermore, evaporation should be prevented during storage by using tightly sealed bags.

#### 10.2.1.1 Full Thickness Skin

Full thickness skin consisting of SC, viable epidermis, and dermis (Fig. 10.1a) is usable for permeation studies (diffusion through the skin, see also Sect. 10.4) as well as penetration studies



**Fig. 10.1** Different human skin membranes for absorption studies: (a) full thickness skin, (b) dermatomed skin, (c) heat separated epidermis, and (d) enzyme split stratum corneum (According to Schaefer et al. 2008)

(see Sect. 10.5), the latter addressing the substance distribution in the different skin layers. For skin permeation studies, the following aspects are noticeable: Hydrophilic substances often cause very long lag-times and may thus require extremely long observation periods. This holds true also for lipophilic substances because of reduced partitioning at the interface between stratum corneum and viable epidermis. However, long observation periods enhance the problem of microbial contamination and change of skin integrity (due to epidermal separation) and should therefore be avoided. To overcome these problems, further segmentation of the skin will be needed.

#### 10.2.1.2 Dermatomed or Split Skin

Dermatomed skin can be prepared by means of a dermatome which performs surface parallel sections, composed of the epidermis and including

the stratum corneum as well as parts of the dermis (Fig. 10.1b). Normally, a slice thickness of 200–400/500  $\mu\text{m}$  is recommended for human skin (OECD 2004b; USEPA 2004). In doing so, the hair follicles will be cut, but the resulting holes will rapidly close during incubation with the acceptor medium due to swelling of the tissue, especially if aqueous donor and receptor fluids are used. During dermatomization care must be taken to avoid mechanical damage of the SC, the main barrier of the skin. To overcome this problem, protection of the skin surface by a plastic foil is indicated (Brain et al. 1998). Typically, dermatomed skin is used for permeation studies, especially if the influence of the hydrophilic layers of the epidermis and dermis should be considered on skin absorption (influence of partition step between SC and viable epidermis/dermis). Moreover, dermatomed skin might be of particular interest to study the fate of


very lipophilic drugs (e.g., pesticides) due to the limited solubility in rather the hydrophilic viable epidermis and dermis.

### 10.2.1.3 Epidermis Sheets

For the separation of epidermis (consisting of SC and viable epidermis, see Fig. 10.1c) and dermis mechanical, thermal, and chemical techniques are available. With all techniques splitting occurs at the basal layer of the epidermis. Mechanical division can be achieved by applying a vacuum to the skin surface (suction technique (Kiistala 1968)). However, only relatively small areas can be treated in such a way. Thermal treatment is most common. This technique was established by Kligman and Christophers (Kligman and Christophers 1963). A specimen of full thickness skin is immersed in water of about 60 °C for a time period of 30–120 s. Afterwards the epidermis sheet can easily be removed from the dermis by means of a forceps or a spatula. Care has to be taken not to mechanically damage the epidermis by this procedure. Before use, the epidermis should be floated on a physiological buffer solution to unfold it completely. It was shown that this treatment does not result in changes of the barrier function. Several methods of chemical separation are reported (Kligman and Christophers 1963; Lee and Parlicharla 1986; Scott et al. 1986). However, due to the use of strong alkaline or acidic solutions, the buffer capacity of the skin will be changed and this may also influence the penetration of ionizable substances. Epidermis sheets provide a reduced resistance to permeation in comparison to dermatomed skin due to the absence of the dermis layer. They are typically used for permeation studies like dermatomed skin.

### 10.2.1.4 Stratum Corneum Sheets

Stratum corneum sheets (Fig. 10.1d) can easily be isolated by incubating full thickness skin or heat separated epidermis in an aqueous buffer solution of pH 7.4 containing trypsin for 24 h at 37 °C (Kligman and Christophers 1963). The SC may be separated from the underlying tissue by gentle shaking. To remove residual amounts of trypsin, the sheets can be rinsed in isotonic aqueous buffer solution pH 7.4. Due to its fragility the



**Fig. 10.2** Permeation experiments with the FD-C. Permeation of flufenamic acid ( $\text{mg}/\text{cm}^2 \pm \text{S.E.}$ ;  $n=3-5$ ) through different skin layers in dependence on the incubation time ( $h$ ) (Figure taken from Wagner et al. (2001))

separated SC should be taken up by a supporting membrane, for example, cellulose membrane (Reichling et al. 2006). In addition, the SC can be lifted by a Teflon foil and afterwards be allowed to dry for storage. After reconstitution with isotonic aqueous buffer pH 7.4, the SC can be used for in vitro experiments.

The influence of the type of skin preparation used in permeation experiments is depicted exemplarily in Fig. 10.2. It is clearly shown that with full thickness skin the permeation is reduced compared to heat separated epidermis and SC, which do not differ in permeability but provide differences in the lag-time. SC sheets are primarily used for mechanistic studies and partition coefficient determination.

### 10.2.1.5 Skin with Impaired Barrier Function

In diseased, injured, or premature skin, the barrier function of the skin is reduced. Skin with an impaired barrier is sometimes also desired for in vitro skin absorption experiments. By stripping with adhesive tape (Wagner et al. 2000) or glue, the outermost cornified cell layers of the SC can be gradually removed, allowing to generate different levels of a decrease in barrier function, corresponding to differently increased permeabilities. In order to compare the results of such experiments, the degree of damage has to be known. In principal this can be done by different

methods, e.g., by determining the amount of SC removed (Hahn et al. 2010) or measuring the transepidermal water loss (TEWL) (Kalia et al. 1996; Russell et al. 2008). Complete removal of stratum corneum and epidermis can best be achieved preferably by rigorous dermatomization rather than by heat separation or trypsinization. The latter two methods may compromise the protein structure of the epidermal/dermal tissue due to precipitation or digestion of proteins.

### 10.2.2 Animal Skin

As human skin has only limited availability, alternatives are necessary. Besides, due to widespread demands in skin absorption studies based on regulatory aspects (e.g., REACH program of the EU (EC 1907/2006, 2006) the pressure to establish alternative models was enforced. In addition, some researchers have ethical and cultural restraints to use human skin (Hikima et al. 2012). Skin from mouse, hairless rat, hamster (cheek pouch), snake (shed skin), pig (ear, flank, abdomen, or back), and cow udder has been suggested as alternatives (Haigh and Smith 1994). However, depending on the animal species used, differences in SC thickness, number of corneocyte layers, hair density, water content, lipid profile and morphology, and different permeabilities in comparison to human skin have been found. Typically the permeability of animal skin was enhanced in comparison to human skin (Bronaugh et al. 1982; Netzlaff et al. 2006b). In general, porcine skin is reported to match human skin best. In addition, porcine skin, especially the ear, is easily available from slaughter houses. However, it has to be kept in mind that porcine skin must not be scalded. Moreover, there are references pointing also to the alternative of cow udder skin (Kietzmann et al. 1993; Netzlaff et al. 2006b; Pittermann and Kietzmann 2006). By the 7th Amendment to the Cosmetic Directive for cosmetic products (EC (2003c) Directive 2003/15/EC; Rossignol MR 2005) a ban of tests on animals and of the marketing of products/ingredients tested on animals came into action in September 2009. Since then only alternative

methods such as animal skin from sources of food supply (pig ear, cow udder) or bioengineered skin surrogates can be used.

### 10.2.3 Bioengineered Skin

For some time bioengineered skin has been introduced in the field of skin research due to the limited supply of human skin, some ethical or cultural restraints to use human skin, and the “3R”-initiative concerning animal welfare (“Refinement, Replacement, Reduction”) (Russell and Russell 1957). Firstly, skin corrosion (Kandárová et al. 2006a, b), sensitization, (Bernard et al. 2000; Spielmann et al. 2000), metabolic phenomena (Gysler et al. 1999), and phototoxicity (Liebsch et al. 1999) were addressed and afterwards skin permeability was evaluated (Dreher et al. 2002). Meanwhile various commercial reconstructed epidermis models are available (Netzlaff et al. 2005) and also accepted for skin corrosion (OECD 2004c, 2006) and irritation testing (OECD 2010). Moreover, many attempts have been made to compare in detail bioengineered skin to human skin and animal skin (Schreiber et al. 2005; Netzlaff et al. 2005, 2007). In two large studies sponsored by the German BMBF (Federal Ministry of Education and Research), the usefulness of the commercially available reconstructed epidermis models Episkin™ (L’Oreal, France), Epiderm® (MatTek corporation, USA), SkinEthic® (SkinEthic Laboratories, France) were tested with nine substances in aqueous solution covering a wide range of lipophilicities and molecular weights (Schäfer-Korting et al. 2006, 2008). As a result, it could be clearly shown that all reconstructed epidermis models were more permeable than human heat separated epidermis and dermatomed porcine skin; however, the rank order of permeability agreed reasonably among these models. Besides, it could be shown that reconstructed epidermis provides less variability in comparison to human and animal skin which is consistent with results from the EDETOX (Evaluations and Predictions of Dermal Absorption of Toxic Chemicals) project (van de Sandt et al. 2004). A review about morphology, biochemical characterization, and application of the bioengineered mod-

els Episkin™, Epiderm®, and SkinEthic® is reported by Netzlaff et al. (2005). Besides, a list of materials tested with Epiderm® is provided by MatTek, USA ([www.mattek.com/pages/products/epider/materials-tested](http://www.mattek.com/pages/products/epider/materials-tested)).

Additional reports are available for other, sometimes self-made, bioengineered skin models. Suhonen et al. reported permeability experiments for 18 compounds in buffered aqueous solutions with a cell culture model based on keratinocytes from rat skin (Suhonen et al. 2003). A close relationship to isolated human cadaver skin was found; however, again the permeability in the cell culture model was enhanced. The group of Mueller-Goymann developed an artificial skin construct based on collagen and HaCaT (human adult low calcium high temperature keratinocytes) cells cultivated at the air-liquid interface (Savic et al. 2009). Investigating the permeation of caffeine and diclofenac from various formulations containing natural surfactant/fatty alcohols mixed emulsifiers they reported that the vehicle skin interaction was mirrored in the artificial skin construct.

A full-thickness commercial skin model, the Phenion® model (Henkel AG & Co.KGaA, Germany) was tested by Ackermann et al. (2010) for percutaneous absorption testing of the OECD (Organisation of economic Co-operation and Development) reference compounds caffeine and testosterone. They concluded that the results closely paralleled human skin (Ackermann et al. 2010). One of the major problems with bioengineered skin is that the sheets must be transferred to standard diffusion cells after the cell layer has been punched out from the cultivating support. To overcome this drawback, Grégoire et al. improved the experimental setup for screening skin absorption with the reconstructed epidermis model Episkin® (Grégoire et al. 2008). By modifying the culture conditions, it was possible to omit bypass diffusion in the inserts. In contrast to studies in static diffusion cells the cell layer no longer has to be punched out. In summary, although there are references suggesting the helpfulness of bioengineered skin in skin absorption studies, the basic problem is the lack of building up a barrier at the same level as natural

human skin (see Fig. 10.2). However, the actual value of such reconstructed skin might be in the development of disease models to simulate specific situations (Semlin et al. 2011).

#### 10.2.4 Artificial Skin Surrogates

Artificial skin surrogates have a long lasting history. Starting from simple membranes of dialysis tubing and polymeric membranes for example of regenerated cellulose, cellulose derivatives, polycarbonate, polyolefines, silicon, etc. more and more complex systems became available (Haigh and Smith 1994). It was recognized early that these very simple membranes do not resemble the skin characteristics and therefore their recommended use was to determine the release of active compounds only (FDA 1997). However, by loading of porous filter materials with lipids, these surrogates better resemble the skin properties especially if native SC lipids are used. Jaeckle et al. used systematic variation of lipid composition to establish suitable membranes which provide properties similar to heat-separated epidermis (Jaeckle et al. 2003). Recently, the Bouwstra group published different methods to establish SC model membranes (De Jager et al. 2004, 2005). For benzoic acid, they could nicely demonstrate that the flux is comparable to human SC (Groen et al. 2008). Based on the PAMPA technique (parallel artificial membrane permeability Assay) that has been successfully applied to predict gastrointestinal and blood–brain barrier absorption (Avdeef 2005) Ottavianai et al. reported on the use of a PAMPA-membrane loaded with an optimized mixture of silicone (70 %) and isopropyl myristate (30 %) to address skin permeation (Ottaviani et al. 2006). They could show for 31 substances of a diverse data set a good correlation to  $k_p$ -values of human skin. Recently, two commercial models based on synthetic lipid mixtures, Strat M® (Joshi et al. 2012) and Skin-PAMPA (Sinkó et al. 2012), have become available.

The Skin-PAMPA assay mimics the lipid phase of the SC using an optimized lipid mixture composed of ceramides, free fatty acids, and cholest-

terol. It can be considered as a refined approach of the method of Ottavani et al. mentioned above. The method was validated comparing the permeation ( $k_p$ ) of various solutes through three different kinds of skin preparations (isolated SC, isolated epidermis, and full thickness skin). Moreover, it could be shown that the assay is capable to predict the permeation in human skin with a reasonable correlation between Skin-PAMPA permeability and Franz cell permeability (Sinkó et al. 2012). When it comes to mimic different skin preparation, the best correlation was found for full thickness skin. Since Skin-PAMPA is a rather new approach, it should be investigated further to prove its reliability and applicability to various scenarios.

The Strat M<sup>®</sup> approach uses a synthetic membrane sandwich composed of polyether sulfone treated with synthetic lipid materials to mimic the human skin. The method was tested using various substances in different formulations in comparison to human cadaver skin in a Franz cell setup. For aspirine, nicotine, and hydrocortisone, the usefulness of the model could be demonstrated showing comparable fluxes in comparison to human skin. Furthermore, comparable vehicle effects, such as penetration enhancement, could be observed for different caffeine formulations. The authors of the study state that the model was investigated against a diverse data set but unfortunately did not state exactly which compounds were tested and what kind of human skin preparation was used in the study (Joshi et al. 2012). Besides, a definition of the lipid mixture composition is missing. Since this is also a novel approach its reliability and versatility should be shown in greater detail in further studies.

---

## 10.3 In Vitro Experimental Setups for Skin Absorption Studies

### 10.3.1 Finite Versus Infinite Dosing

For skin absorption studies one differentiates usually between two different modes of application, finite and infinite dosing. Both terms are defined in the OECD Guideline 428 (OECD 2004b) and more specifically in OECD Guidance

28 (OECD 2004a). In general, finite dosing mimics the “in use” conditions where normally a limited dose of the formulation is applied to the skin. In contrast by infinite dosing a disproportionately high amount of formulation is applied. Typically a maximum of 1–5 mg/cm<sup>2</sup> for powders, up to 10 µl/cm<sup>2</sup> for solutions, and up to 10 mg/cm<sup>2</sup> for semisolid preparations are considered finite doses. One problem with finite dosing is to spread the formulation evenly across the skin surface. Hahn et al. could demonstrate that this effect may influence the results of in vitro skin absorption studies depending on the applied drug (Hahn et al. 2012). Also, the finite dose kinetics of drug concentration over time are usually quite complex due to multifactorial overlapping processes such as the depletion of active in the donor phase (which should usually lead to a decrease in the rate of absorption), changes in the donor composition which affect the skin permeability, and elimination of the active due to metabolism and systemic clearance to name but the most relevant. The complexity of the problem shall be illustrated by the following example. If the formulation is applied without an occlusive dressing, the donor concentration may increase due to evaporation of components of the vehicle and consequently increase the rate of absorption. This may even lead to over-saturation or recrystallization of formulation components or the active on the skin which further complicates matters. Normally true finite dosing is assumed if the donor concentration depletes to at least 10 % of the initial concentration of the applied formulation after about 20–24 h (WHO 2006).

By infinite dosing, the amount of formulation should be large enough to assure that practically no donor depletion occurs. From that it follows that a maximum rate of absorption is gained and maintained over the whole experimental period. Typically the steady state flux is determined and based on that the apparent permeability coefficient is calculated. In between of finite and infinite dosing all transient cases are possible. For more details on the effects of finite, semifinite, and infinite dosing on skin invasion see Chapter 1 “Basic mathematics in skin permeation of drugs” in this volume.



As stated before finite dosing is normally related to “in use” conditions. However, the conditions during bathing or wearing closely fitting clothes are more realistic depicted by infinite dosing (WHO 2006).

### 10.3.2 Open Versus Occluded Dosing


Occlusion during in vitro skin absorption experiments will influence the results in different ways. Normally these effects are limited to the finite dose case, because for infinite dosing practically no changes of the donor compartment will take place. In the open system, due to evaporation of vehicle compounds, the concentration of active increases and may even achieve supersaturation. This changes the conditions completely depending on the magnitude of evaporation. Surber and Smith have reported this phenomenon as metamorphosis of the formulation (Surber and Smith 2005). On the other hand, if the active is volatile the concentration will decrease during experimental time. In this case, it is essential to determine the rate of evaporation during the experiment by collecting the volatile substance, for example, by using an adsorption trap (adsorptive powder) mounted on top of the diffusion cell (Rauma et al. 2013). This is essential if mass balance is addressed (Kasting and Miller 2006).

### 10.3.3 Diffusion Cells

In the past, many different protocols have been used to address skin invasion (ECETOC 1993; EC 2003a, b; SCCNFP 2003; SCCNFP/0690/03 2003; EC 2004; WHO 2006; SCCS/1358/10 2010; EFSA 2012). This results in problems of comparability of results. Meanwhile in 2004 the OECD Guideline 428 and OECD Guidance 28 became effective and provide general rules for conducting in vitro tests for dermal absorption (OECD 2004a, b). In principal special protocols are allowed; however, deviations from the recommended procedures should be restricted and have to be rationally motivated on a case-to-case basis.

In principal two different types of test chambers are available. These are either upright/vertical (Fig. 10.3a) or side-by-side/horizontal cells (Fig. 10.3b) with receptor volumes from 0.5 to 15 ml and application areas of about 0.2–2 cm<sup>2</sup> (Brain et al. 1998). As by manufacturing processes dimensions may vary in certain limits calculation of data has to be related to individual cells. Vertical cells are preferable for testing semisolid formulations which can be spread on the incubation area analogously to the in vivo situation. In addition, it is easy to realize both occlusive effects by capping the donor chamber and in-use condition (nonoccluded) by leaving the donor chamber open. Usually, in vertical cells the receptor phase is mixed by stirring with a magnetic bar. Side-by-side cells consist of two chambers separated by a membrane. Both sides are stirred leading to highly controlled diffusion conditions, including continuous concentration equilibrium in both chambers and well-defined unstirred layers. Therefore, side-by-side diffusion cells are preferable for kinetic studies, especially if solutions are tested. For testing semisolid preparations, the design of side-by-side diffusion cells has to be changed by replacing the donor side by a static system without stirring (Feldmann and Maibach 1969; Bronaugh and Stewart 1984, 1985). For vertical as well as side-by-side diffusion cells, the static and the flow-through mode are available. Using the static mode the receptor phase is not replaced continuously except for the volume exchange during sampling. This leads to a constant increase of substance in the receptor fluid, and depending on the saturation concentration of compound diffusion may be affected. In general it is agreed upon that until reaching a maximum of 10% saturation concentration in the acceptor, diffusion will not be influenced (known as sink conditions). Therefore, care must be taken not to exceed this limit. One possibility to overcome this problem is to exchange the receptor medium completely at each sampling point. However, it has to be considered that problems with compound quantification, due to quantification limits, and air bubbles may occur.

Because of the easy handling the most widely used static diffusion cell is the Franz diffusion



**Fig. 10.3** Sketch of a static vertical Franz diffusion-cell (a), static side-by-side diffusion cell (b), after static side-by-side diffusion cell, flow-through cell (c), and Saarbruecken penetration model (d)

cell which was introduced in 1975 (Franz 1975). As an alternative a flow-through version can be used (Fig. 10.3c). In this mode the receptor volume is continuously replaced by means of a pump, which more or less mimics the vivo conditions of drainage by the systemic circulation and facilitates maintaining sink conditions. A typical flow-through cell, based on a side-by-side diffusion cell, has been designed by Bronaugh and Stewart (1985). It has to be kept in mind that flow rate, chamber volume, and detection limit are related variables. The flow rate has to be adjusted in a way that during the entire experimental time sink conditions apply in the receptor chamber, the amount can be detected, and proper mixing exists. In addition adsorption of analytes to the tubing used to pump the receptor medium may influence the results. A real benefit of flow-through systems especially for higher numbers of tests such as in an industrial setting is that continuous replacement of the receptor fluid can easily be automated (Moody 1997, 2000). Automation of sampling is available for vertical

diffusion cells too, for example, described by Solich et al. (2001, 2003). In general several comparative studies have shown the equivalence of static and flow-through cells (Bronaugh and Maibach 1985; Bronaugh and Stewart 1985). Due to the easy handling and realization of in-use application conditions, static Franz diffusion cells are generally preferred. However, for studies where metabolic effects are involved flow-through systems like the Bronaugh cell are superior because the continuous solvent replacement better mimics the in vivo situation (Bronaugh 2004a, b).

### 10.3.4 Barrier Integrity Check

Barrier integrity has to be checked prior or after in vitro skin invasion experiments. Common physical methods are measurement TEWL or transcutaneous resistance or alternatively the measurement of the permeation of a marker substance, mostly tritiated water. TEWL measurements are well

established for in vivo studies. For in vitro experiments, it is strongly recommended to use a closed chamber measurement setup (e.g., Aquaflox AF200, Biox, London, UK; VapoMeter, Delfin Technologies, Kuopio, Finland). In contrast, Netzlaff et al. reported that devices using the open chamber principle (e.g., the Tewameter<sup>®</sup> TM 300, Courage-Khazaka Electronic, Koeln, Germany) are not sensitive enough to detect small defects of the skin which nonetheless influence skin permeation (Netzlaff et al. 2006a). However, it has to be kept in mind that TEWL threshold values that might indicate a violation of barrier integrity depend on the TEWL instrument used as well as the skin preparation and therefore no general limits can be provided (Elkeeb et al. 2010). Using tritiated water as a marker is also a well-established method although the exclusion criteria for damaged skin are nowadays under discussion. Too many samples may be rejected using a permeability coefficient of water of  $2.5 \times 10^{-3}$  cm/h as the upper limit to reject cells with damaged barrier (Wilkinson et al. 2004). Another problem is the use of tritiated water before doing the experiment. During the removal of the remaining tritiated water barrier damage may occur. Therefore, the use of tritiated water must be evaluated critically.

### 10.3.5 Temperature

Diffusion processes are temperature dependent and therefore in vitro permeation experiments should be carried out at the physiological temperature of the skin surface, i.e.,  $32 \pm 1$  °C (OECD 2004a, b). This should be maintained during the entire experimental duration. If diffusion cells with a water jacket are used in line configuration may cause a temperature gradient between the first cell and the last cell. To overcome this problem parallel connection of the cells is recommended. Other possibilities are to insert the cells in a water bath (in this case care must be taken that no water enters the cells) or a metal bloc or alternatively to store the cells in an oven with constant temperature (Schäfer-Korting et al. 2006).

### 10.3.6 Selection of Receptor Fluid

The selection of the right receptor fluid is essential for the results. The following points have to be considered: the receptor fluid should enable sufficient solubility of the active compound under investigation (see also Sect. 10.3.3 for explanation of sink conditions), allow unhindered partitioning of the active from the skin to the receptor fluid, and not disturb the barrier integrity of the skin. For water soluble compounds, normal saline or isotonic buffer systems of pH 7.4 are appropriate. To prevent microbial influences on skin integrity preservatives, preferentially sodium azide (0.05 % wt/V), should be added. To maintain viability of fresh skin cell culture medium is feasible. For lipophilic substances additives to enhance the solubility are needed (OECD 2004a). For example, for essential oils ethanol water mixtures of different concentrations may be used (Reichling et al. 2006). Furthermore, the addition of surfactants (Challapalli and Stinchcomb 2002; OECD 2004a), bovine serum albumin (Dal Pozzo et al. 1991), or cyclodextrines (Sclafani et al. 1995) are reported. In all these cases, the influence of the additives on permeability must be clarified, e.g., by testing different concentrations of a solubilizer. Besides, it has to be considered that the analytical procedure may be affected by the additives.

### 10.3.7 Duration of Exposure and Sampling Period

Exposure times of the skin with the formulation should always reflect in-use conditions and consequently will vary, e.g., for rinse-off products exposure time will only be a few minutes. However, the sampling time should cover at least a period of 24 h (OECD 2004b). For kinetic studies, e.g., determination of permeability coefficients under infinite conditions or lag time (i.e., the time to reach steady state of diffusion) an extension to 48 h may be needed. Even longer sampling times normally result in impairment of the skin barrier and freshness and the results are questionable. Moreover, where static cells are

concerned a sufficiently large number of sampling points should be planned so that a representative number of data points are available especially during steady state (rule of thumb: preferentially at least five sampling points which are evenly spread out during steady state) to describe the permeation kinetics properly. Especially concentration changes between sampling points should be large enough to be detected by the analytical procedure.

### 10.3.8 Quantification Methods

For risk assessment frequently radioactive labeled compounds are used (Poet and McDougal 2002). In this context, it has to be demonstrated that the intact molecule is measured by scintillation counting. In addition one cannot fully exclude that labeling may result in a change of permeability properties. Meanwhile new highly sensitive and selective quantification methods are available, e.g., high-performance liquid chromatography (HPLC), Liquid chromatography-mass spectrometry (LC-MS-MS), etc. With these methods simultaneous quantification of the mother compound as well as metabolites or degradation products is possible. Therefore, it is recommended to use such methods preferentially.

### 10.3.9 Influence of Thickness of Skin Preparation

It is well known that the thickness of the skin preparation may influence the results of *in vitro* skin absorption experiments in various manners depending on compound, formulation, and dosing (finite/infinite) (Wagner et al. 2002; Veccia and Bunge 2003; EDETOX 2004; Wilkinson et al. 2004, 2006; Henning et al. 2008, 2009). Due to the complexity of the skin invasion process and lack of data, relations to physico-chemical characteristics are difficult to establish. However, in general if using full thickness skin steady state conditions may often not be achieved

within feasible experimental time periods (<48 h, in well-founded exceptional cases up to 72 h). Therefore, it is generally recommended to use split-thickness human skin for permeation studies, if possible (Van De Sandt et al. 2000; SCCS/1358/10 2010). If full thickness skin is needed, rational has to be provided for that. Moreover, the use of epidermal membranes must be justified. Due to their fragility, heat separated epidermis may cause problems with tape stripping which is needed for establishing a mass balance to address the content inside the SC in finite dose experiments especially if skin absorption of pesticides etc. is addressed. In this case, the amount in the SC is often considered as not absorbed depending on substance properties and application (EFSA 2012).

### 10.3.10 Number of Experiments/Replicates

As basic criteria concerning the number of samples to assess *in vitro* absorption of cosmetic ingredients eight samples from four different donors are recommended by (SCCS/1358/10 2010). In addition a minimum of 0.64 cm<sup>2</sup> skin area should be covered by the formulation (SCCS/1358/10 2010). Furthermore, the total recovery should be in the range of 85–115% (SCCS/1358/10 2010). However, for risk assessments of chemicals the recovery limits are 90–110% but may be extended in special justified cases (OECD 2004b).

### 10.3.11 Segmentation of Skin in Different Skin Layers

To localize the active compound in different skin layers, e.g., to determine depot effects, a segmentation of the skin is needed. Incubation of the skin can be done either in diffusion cells or in a special apparatus, the so-called Saarbruecken penetration model (SB-M, Fig. 10.3d) (Wagner et al. 2000). In contrast to diffusion cells, the SB-M

does not have a liquid receptor phase and therefore the original hydration state of the skin is preserved. Normally full thickness skin is used for this model, and experiments are done for a series of incubation times to obtain drug-concentration skin depth profiles. For more details, please refer to (Wagner et al. 2000; Melero et al. 2011).

Skin dissection can be done first by tape stripping to remove the stratum corneum layer-by-layer using adhesive tapes and afterwards by segmentation of epidermis and dermis into surface parallel slices by means of a cryomicrotome. Skin segmentation in in vitro absorption experiments is only meaningful if skin of a certain thickness, e.g., dermatomed or full thickness skin, is used.

#### **10.3.11.1 Removal of the Stratum Corneum by Tape Stripping**

Many protocols exist for tape stripping in vitro as well as in vivo (Shah et al. 1998; Surber et al. 1999; Voegeli et al. 2007; Lademann et al. 2009; Melero et al. 2011). Normally tape stripping is not possible for epidermis sheets due to their fragility. Furthermore, for longer incubation times or strong interaction of excipients with the SC tape stripping may be altered.

To obtain valid results, the following points have to be considered:

The surface of the skin must be properly cleaned, for example, by cotton swabs or by a washing procedure. The washing step removes the remaining formulation from the skin surface and thus assures that the tape strips may stick to the skin surface. Especially, organic solvents should be avoided due to the effect of substance extraction at least from the outermost stratum corneum layers.

For homogeneous tape stripping, the problem of wrinkles has to be eliminated and a constant pressure has to be applied. That can be done, for example, by mounting the skin disk under stretching on cork disks in a special apparatus (Wagner et al. 2000) and charging each strip with a constant weight for a predetermined time period or using a special roller (Lademann et al. 2009). Furthermore, to be able to calculate the

corresponding skin depths the removed amount of stratum corneum has to be determined. This can be done, e.g., by weighing (Russell and Guy 2012) or by a more advanced method such as infrared densitometry (Hahn et al. 2010; Franzen et al. 2012) protein extraction and quantification (Dreher et al. 2005) or other optical methods (Weigmann et al. 2003). For human skin and pig skin, it could also be demonstrated that infrared densitometry offers the possibility to determine the point of total removal of the stratum corneum (Hahn et al. 2010; Franzen et al. 2012). For more detailed instructions see (Melero et al. 2011).

#### **10.3.11.2 Segmentation of the Deeper Skin Layers Consisting of Viable Epidermis and Dermis (Cryosectioning)**

The best way for segmentation of the deeper skin layers is surface parallel cryosectioning. After removal of the SC the skin specimen is mounted on a metal bloc, the surface is adjusted horizontally, and rapidly frozen, for example, by expanding carbon dioxide. Subsequently, the sample is transferred into a cryomicrotome and the skin is segmented into horizontal slices. The corresponding skin depth can easily be related to the weight of the slice. For details see reference (Melero et al. 2011).

---

## **10.4 Results Obtained from Permeation Studies**

Permeation studies are normally conducted to determine the transdermal/systemic availability of a compound. Therefore, the main experimental parameter which is addressed is the amount permeated per cm<sup>2</sup> into the receptor compartment over time. Two different dosing regimens are available. The infinite dosing regimen serves to determine kinetic constants such as the steady state flux or the apparent permeability coefficient and lag time, whereas finite dosing evaluates the amount absorbed after a certain time. Additionally by applying the technique of mass balance the

fate of a compound can be evaluated (i.e., the percentage that stays on the skin surface, enters the SC or other parts of the skin, etc.).

### 10.4.1 Infinite Dosing Studies

Permeation studies using infinite dosing address the steady state flux of a compound from a formulation through a given membrane, e.g., SC, epidermis, dermatomed skin, or full thickness skin, according to Fick's law of diffusion. The steady state flux value  $J_{ss}$  is calculated from the linear part of a diagram of the amount of compound permeated into the receptor phase per area versus time. At the beginning of the experiment, the membrane will first be filled up with permeant until saturation (steady state) is reached. The extrapolation of the linear steady state intersects with the time-axis at the lag time  $t_{lag}$  which can be used to calculate the apparent diffusion coefficient. Moreover, based on the steady state flux ( $J_{ss}$ ) the apparent permeability coefficient  $K_p = J_{ss}/C_v$ , with  $C_v$  = concentration in the vehicle can be calculated. Permeability coefficients may be used for the comparison of different formulations. Furthermore, the maximum flux ( $J_{ss(max)}$ ) of the solute, which denotes the maximal possible dermal delivery from a given vehicle, can be estimated by  $K_{p(max)} = J_{ss(max)}/C_{ss}$ , with  $C_{ss}$  = saturation concentration of the solute in the vehicle (Roberts et al. 2002; Magnusson et al. 2004). For more details see Chap. 1 "Basic Mathematics in Skin Permeation of Drugs" in this volume (Selzer et al. 2013).

### 10.4.2 Finite Dosing Studies

Based on the permeated amount of compound into the receptor phase per  $cm^2$  versus time dependency the amount permeated can be calculated for selected time points. These values can serve for comparison of different formulations. Moreover, the highest flux value (Also: peak flux,  $J_{peak}$ ) during the experimental time period can be determined. For finite dosing studies after the end of the


experiment a mass balance is inevitable. Total recovery should be in the range of 85–115% according to guidelines or references (SCCNFP/0690/03 2003; SCCS/1358/10 2010). However, for risk assessments of chemicals the recovery limits are set to 90–110% but may be extended in special justified cases (OECD 2004b).

---

## 10.5 Results Obtained from Penetration Studies

The scope of penetration studies is to determine the distribution of a compound within the different skin layers. Therefore, skin segmentation is needed (see Sect. 10.3.11). Within each skin segment the amount of drug must be determined selectively and completely. For doing that an extraction procedure has to be established and validated which allows the determination of very low concentrations with a high accuracy and recovery. This may lead to complications if quantification techniques like HPLC, LC-MS, etc. are used. Furthermore, due to quantification limits consecutive segments may need to be pooled (Wagner et al. 2000; Hansen et al. 2008). However, this reduces the precision of the results. Besides, for the construction of concentration skin depth profiles the exact segment position in the skin has to be known (Hahn et al. 2010). Examples for SC profiles of infinite dosing and finite dosing are shown in Fig. 10.4.

Due to potential contamination by not completely removed formulation often the two first strips are discarded. Based on such profiles diffusion parameters according to Fick's law can be calculated. For more details, please refer to reference (Selzer et al. 2013). Apart from that additional information can be gained. Wagner et al. demonstrated by applying a model based on a Michaels Menten kinetic that the time to reach 50% of saturation within the SC can be related to the permeability coefficients for heat-separated epidermis sheets (Wagner et al. 2002). Moreover, calculation of total amounts in different skin layers, e.g., SC and deeper skin layer, may allow the identification of skin depots.



**Fig. 10.4** Stratum corneum concentration-depth profiles of 0.9% flufenamic acid in wool wax alcohol ointment for the infinite (a) and finite dose case (b) in dependency of incubation time. Standard deviations are not shown for clarity (Data taken H. Wagner, PhD thesis, Charakterisierung des Arzneistofftransportes in Humanhaut unter in-vitro und in-vivo Bedingungen sowie unter Berücksichtigung des Einflusses zweier in-vitro Testsysteme” (2001), Saarland University, Saarbruecken, Germany)

## Conclusion

In vitro approaches to study skin absorption are useful tools in dermal product development as well as in risk assessment. Within the last years enormous efforts have been done to standardize experimental setups (SCCNFP/0690/03 2003; OECD 2004a, b; WHO 2006). However, due to the diversity of the requirements deviations from the standard protocols are often needed. This chapter provides a basic overview of the main topics of in vitro skin absorption techniques. Especially, different skin layers and artificial membranes for permeation studies are addressed. In general, the major

problem for advanced data interpretation is the lack of systematic experimental studies and standardized procedures.

## References

- Ackermann K, Lombardi Borgia S, Korting HC, Mewes KR, Schäfer-Korting M (2010) The phenion® full-thickness skin model for percutaneous absorption testing. *Skin Pharmacol Physiol* 23:105–112
- Avdeef A (2005) The rise of PAMPA. *Expert Opin Drug Metab Toxicol* 1:325–342
- Bernard FX, Barrault C, Deguercy A, De Wever B, Rosdy M (2000) Development of a highly sensitive in vitro phototoxicity assay using the SkinEthic™ reconstructed human epidermis. *Cell Biol Toxicol* 16:391–400
- Brain KR, Walters KA, Watkinson AC (1998) Investigation of skin permeation in vitro. In: Roberts M, Walters KA (eds) *Dermal absorption and toxicity assessment*, vol 91. Marcel Dekker, New York, pp. 161–187
- Bronaugh RL (2004a) Methods for in vitro percutaneous absorption. In: Zhai H, Maibach H (eds) *Dermatotoxicology*, 6th ed. CRC Press, New York, pp 520–526
- Bronaugh RL (2004b) Methods for in vitro skin metabolism studies. In: Zhai H, Maibach H (eds) *Dermatotoxicology*, 6th ed. CRC Press, New York, pp 622–630
- Bronaugh RL, Maibach HI (1985) Percutaneous absorption of nitroaromatic compounds: in vivo and in vitro studies in the human and monkey. *J Invest Dermatol* 84:180–183
- Bronaugh RL, Stewart RF (1984) Methods for in vitro percutaneous absorption studies III: hydrophobic compounds. *J Pharm Sci* 73:1255–1258
- Bronaugh RL, Stewart RF (1985) Methods for in vitro percutaneous absorption studies. IV: the flow-through diffusion cell. *J Pharm Sci* 74:64–67
- Bronaugh RL, Stewart RF, Congdon ER (1982) Methods for in vitro percutaneous absorption studies II. Animal models for human skin. *Toxicol Appl Pharmacol* 62:481–488
- Bronaugh RL, Stewart RF, Simon M (1986) Methods for in vitro percutaneous absorption studies VII: use of excised human skin. *J Pharm Sci* 75:1094–1097
- Challapalli PVN, Stinchcomb AL (2002) In vitro experiment optimization for measuring tetrahydrocannabinol skin permeation. *Int J Pharm* 241:329–339
- Dal Pozzo A, Liggeri E, Delucca C, Calabrese G (1991) Prediction of skin permeation of highly lipophilic compounds: in vitro model with a modified receptor phase. *Int J Pharm* 70:219–223
- De Jager MW, Gooris GS, Dolbnya IP, Bras W, Ponc M, Bouwstra JA (2004) Novel lipid mixtures based on synthetic ceramides reproduce the unique stratum corneum lipid organization. *J Lipid Res* 45:923–932
- De Jager MW, Gooris GS, Ponc M, Bouwstra JA (2005) Lipid mixtures prepared with well-defined synthetic

- ceramides closely mimic the unique stratum corneum lipid phase behavior. *J Lipid Res* 46:2649–2656
- DI G, Gooris GS, Ponec M, Bouwstra JA (2008) Two new methods for preparing a unique stratum corneum substitute. *Biochim Biophys Acta Biomembranes* 1778:2421–2429
- Dreher F, Patouillet C, Fouchard F, Zanini M, Messenger A, Roguet R et al (2002) Improvement of the experimental setup to assess cutaneous bioavailability on human skin models: dynamic protocol. *Skin Pharmacol Appl Skin Physiol* 15:31–39
- Dreher F, Modjtahedi BS, Modjtahedi SP, Maibach HI (2005) Quantification of stratum corneum removal by adhesive tape stripping by total protein assay in 96-well microplates. *Skin Res Technol* 11:97–101
- EC (2003a) European Commission, Health & Consumer protection directorate, directorate E, Food safety: plant health, animal health and welfare, international questions, Flufenacet 7469/VI/98, Brussels, Belgium, <https://www.fluoridealert.org/wp-content/pesticides/flufenacet.eu.july.2003.pdf>
- EC (2003b) European Commission, Health & Consumer protection directorate, directorate E, Food safety: plant health, animal health and welfare, international questions. Propineb SANCO/7574/VI/97-final, Brussels, Belgium, [http://ec.europa.eu/food/fs/sfp/ph\\_ps/pro/eva/existing/list1-34\\_en.pdf](http://ec.europa.eu/food/fs/sfp/ph_ps/pro/eva/existing/list1-34_en.pdf)
- EC (2003c) Directive 2003/15/EC of the European Parliament and of the Council of 27 February 2003, <http://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A32003L0015>
- EC (2004) Guidance on dermal absorption, Sanco/22s2/2000rev.7, European Commission, Brussels, Belgium, [http://ec.europa.eu/food/plant/docs/pesticides\\_ppp\\_app-proc\\_guide\\_tox\\_dermal-absorp-2004.pdf](http://ec.europa.eu/food/plant/docs/pesticides_ppp_app-proc_guide_tox_dermal-absorp-2004.pdf)
- EC 1907/2006 (2006) Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH), European Commission, Brussels, Belgium, [http://eur-lex.europa.eu/legal-content/EN/TXT/?uri=uriserv:OJ.L\\_.2006.396.01.0001.01.ENG](http://eur-lex.europa.eu/legal-content/EN/TXT/?uri=uriserv:OJ.L_.2006.396.01.0001.01.ENG)
- ECETOX (1993) ECETOX (European Centre for Ecotoxicology and Toxicology of Chemicals), Percutaneous absorption. Monograph 020, ECETOX, Brussels, Belgium, <http://www.ecetoc.org/publications/monographs/>
- EDETOX (2004) Evaluations and predictions of dermal absorption of toxic chemicals, Final report for dissemination, Faith M. Williams, [https://ec.europa.eu/research/quality-of-life/ka4/pdf/report\\_edetox\\_en.pdf](https://ec.europa.eu/research/quality-of-life/ka4/pdf/report_edetox_en.pdf)
- EEC (1976) Council directive on the approximation of laws of the Member States relating to cosmetic products (76/768/EEC), European Commission, Brussels, Belgium
- EFSA (2012) Panel on Plant Protection Products and their Residues, Guidance on Dermal Absorption, *EFSA Journal* 10(4):2665. DOI: 10.2903/j.efsa.2012.2665 <https://www.efsa.europa.eu/en/efsajournal/pub/2665>
- Elkeeb R, Hui X, Chan H, Tian L, Maibach HI (2010) Correlation of transepidermal water loss with skin barrier properties in vitro: comparison of three evaporimeters. *Skin Res Technol* 16:9–15
- FDA (1997) U.S. Food and Drug Administration, Silver Spring, MD 20993, USA Guidance SUPAC-SS: Nonsterile Semisolid Dosage Forms; Scaling-Up and Post-Approval Changes: Chemistry, Manufacturing and Controls; In Vitro Release Testing and In Vivo Bioequivalence Documentation. Food and Drug Administration, Silver Spring, MD 20993, USA, <http://www.fda.gov/ucm/groups/fdagov-public/@fdagov-drugs-gen/documents/document/ucm070930.pdf>
- Feldmann RJ, Maibach HI (1969) Percutaneous penetration of steroids in man. *J Invest Dermatol* 52:89–94
- Franz TJ (1975) Percutaneous absorption. On the relevance of in vitro data. *J Invest Dermatol* 64:190–195
- Franzen L, Windbergs M, Hansen S (2012) Assessment of near-infrared densitometry for in situ determination of the total stratum corneum thickness on pig skin: influence of storage time. *Skin Pharmacol Physiol* 25:249–256
- Grégoire S, Patouillet C, Noé C, Fossa I, Benech Kieffer F, Ribaud C (2008) Improvement of the experimental setup for skin absorption screening studies with reconstructed skin EPISKIN®. *Skin Pharmacol Physiol* 21:89–97
- Gysler A, Kleuser B, Sippl W, Lange K, Korting HC, Hölting HD et al (1999) Skin penetration and metabolism of topical glucocorticoids in reconstructed epidermis and in excised human skin. *Pharm Res* 16:1386–1391
- Hahn T, Hansen S, Neumann D, Kostka KH, Lehr CM, Muys L et al (2010) Infrared densitometry: a fast and non-destructive method for exact stratum corneum depth calculation for in vitro tape-stripping. *Skin Pharmacol Physiol* 23:183–192
- Hahn T, Selzer D, Neumann D, Kostka KH, Lehr CM, Schaefer UF (2012) Influence of the application area on finite dose permeation in relation to drug type applied. *Exp Dermatol* 21:233–235
- Haigh JM, Smith EW (1994) The selection and use of natural and synthetic membranes for in vitro diffusion experiments. *Eur J Pharma Sci* 2:311–330
- Hansen S, Henning A, Naegel A, Heisig M, Wittum G, Neumann D et al (2008) In-silico model of skin penetration based on experimentally determined input parameters. Part I: experimental determination of partition and diffusion coefficients. *Eur J Pharm Biopharm* 68:352–367
- Harrison SM, Barry BW, Dugard PH (1984) Effects of freezing on human skin permeability. *J Pharm Pharmacol* 36:261–262
- Hawkins GS Jr, Reifenrath WG (1984) Development of an in vitro model for determining the fate of chemicals applied to skin. *Fundam Appl Toxicol* 4:S133–S144
- Henning A, Neumann D, Kostka KH, Lehr CM, Schaefer UF (2008) Influence of human skin specimens consisting of different skin layers on the result of in vitro



- permeation experiments. *Skin Pharmacol Physiol* 21:81–88
- Henning A, Schaefer UF, Neumann D (2009) Potential pitfalls in skin permeation experiments: influence of experimental factors and subsequent data evaluation. *Eur J Pharm Biopharm* 72:324–331
- Hikima T, Kaneda N, Matsuo K, Tojo K (2012) Prediction of percutaneous absorption in human using three-dimensional human cultured epidermis LabCyte EPI-MODEL. *Biol Pharm Bull* 35:362–368
- Jaeckle E, Schaefer UF, Loth H (2003) Comparison of effects of different ointment bases on the penetration of ketoprofen through heat-separated human epidermis and artificial lipid barriers. *J Pharm Sci* 92:1396–1406
- Joshi V, Brewster D, Colonero P (2012) In vitro diffusion studies in transdermal research: a synthetic membrane model in place of human skin. *Drug Dev Deliv*. Issue: March 2012, <http://www.drug-dev.com/Main/Back-Issues/In-Vitro-Diffusion-Studies-in-Transdermal-Research-509.aspx>
- Kalia YN, Pirot F, Guy RH (1996) Homogeneous transport in a heterogeneous membrane: water diffusion across human stratum corneum in vivo. *Biophys J* 71:2692–2700
- Kandárová H, Liebsch M, Schmidt E, Genschow E, Traue D, Spielmann H et al (2006a) Assessment of the skin irritation potential of chemicals by using the SkinEthic reconstructed human epidermal model and the common skin irritation protocol evaluated in the ECVAM skin irritation validation study. *ATLA Altern Lab Anim* 34:393–406
- Kandárová H, Liebsch M, Spielmann H, Genschow E, Schmidt E, Traue D et al (2006b) Assessment of the human epidermis model SkinEthic RHE for in vitro skin corrosion testing of chemicals according to new OECD TG 431. *Toxicol In Vitro* 20:547–559
- Kasting GB, Miller MA (2006) Kinetics of finite dose absorption through skin 2: volatile compounds. *J Pharm Sci* 95:268–280
- Kietzmann M, Loscher W, Arens D, Maass P, Lubach D (1993) The isolated perfused bovine udder as an in vitro model of percutaneous drug absorption of dexamethasone, benzoyl peroxide, and etofenamate. *J Pharmacol Toxicol Meth* 30:75–84
- Kiistala U (1968) Suction blister device for separation of viable epidermis from dermis. *J Invest Dermatol* 50:129–137
- Kligman AM, Christophers E (1963) Preparation of isolated sheets of human stratum corneum. *Arch Dermatol* 88:702–705
- Lademann J, Richter H, Schaefer UF, Blume-Peytavi U, Teichmann A, Otberg N et al (2006) Hair follicles – a long-term reservoir for drug delivery. *Skin Pharmacol Physiol* 19:232–236
- Lademann J, Richter H, Teichmann A, Otberg N, Blume-Peytavi U, Luengo J et al (2007) Nanoparticles – an efficient carrier for drug delivery into the hair follicles. *Eur J Pharm Biopharm* 66:159–164
- Lademann J, Jacobi U, Surber C, Weigmann HJ, Fluhr JW (2009) The tape stripping procedure – evaluation of some critical parameters. *Eur J Pharm Biopharm* 72:317–323
- Lee G, Parlicherla P (1986) An examination of excised skin tissues used for in vitro membrane permeation studies. *Pharm Res* 3:356–359
- Liebsch M, Traue D, Barrabas C, Spielmann H, Gerberick GF, Prevalidation of the EpiDerm™ phototoxicity test; Alternatives to Animal Testing II. In: Clark D G, Lisansky SG, and Macmillan R. (ed.) COLIPA, Brussels, Belgium, pp.160–167.
- Magnusson BM, Anissimov YG, Cross SE, Roberts MS (2004) Molecular size as the main determinant of solute maximum flux across the skin. *J Invest Dermatol* 122:993–999
- Suhonen TM, Pasonen-Seppänen S, Kirjavainen M, Tammi M, Tammi R, Urtti A (2003) Epidermal cell culture model derived from rat keratinocytes with permeability characteristics comparable to human cadaver skin. *Eur J Pharm Sci* 20:107–113
- Melero A, Hahn TM, Schaefer UF, Schneider M (2011) In vitro human skin segmentation and drug concentration-skin depth profiles. *Methods Mol Biol* 763:33–50
- Moghimi HR, Barry BW, Williams AC (1999) Stratum corneum and barrier performance: a model lamellar structural approach. In: Bronaugh RL, Maibach H (eds) *Drugs – cosmetics – mechanisms – methodology*. Marcel Dekker, New York, Basel, Hong Kong, pp 515–553
- Moody RP (1997) Automated in Vitro Dermal Absorption (AIVDA): a new in vitro method for investigating transdermal flux. *ATLA Altern Lab Anim* 25:347–357
- Moody RP (2000) Automated In Vitro Dermal Absorption (AIVDA): predicting skin permeation of atrazine with finite and infinite (swimming/bathing) exposure models. *Toxicol In Vitro* 14:467–474
- NAFTA (2009) Detailed Review and Harmonisation of Dermal Absorption Practices – Position Paper on Use of in vitro Dermal Absorption Data in Risk Assessment. NAFTA Absorption Group, Washington, DC 20508, USA
- Netzlaff F, Lehr CM, Wertz PW, Schaefer UF (2005) The human epidermis models EpiSkin®, SkinEthic® and EpiDerm®, an evaluation of morphology and their suitability for testing phototoxicity, irritancy, corrosivity, and substance transport. *Eur J Pharm Biopharm* 60:167–178
- Netzlaff F, Kostka KH, Lehr CM, Schaefer UF (2006a) TEWL measurements as a routine method for evaluating the integrity of epidermis sheets in static Franz type diffusion cells in vitro. Limitations shown by transport data testing. *Eur J Pharm Biopharm* 63:44–50
- Netzlaff F, Schaefer UF, Lehr CM, Meiers P, Stahl J, Kietzmann M et al (2006b) Comparison of bovine udder skin with human and porcine skin in percutaneous permeation experiments. *ATLA Altern Lab Anim* 34:499–513
- Netzlaff F, Kaca M, Bock U, Haltner-Ukomadu E, Meiers P, Lehr C-M et al (2007) Permeability of the recon-

- structed human epidermis model Episkin® in comparison to various human skin preparations. *Eur J Pharm Biopharm* 66:127–134
- OECD (2004a) Guidance Document for the Conduct of Skin Absorption Studies, OECD series on testing and assessment Nr. 28, OECD Publishing, Paris. DOI: <http://dx.doi.org/10.1787/9789264078796-en>
- OECD (2004b) Test No. 428: Skin Absorption: In Vitro Method, OECD Publishing, Paris. DOI: <http://dx.doi.org/10.1787/9789264071087-en>
- OECD (2004c) Test No. 431: In Vitro Skin Corrosion: Human Skin Model Test, OECD Publishing, Paris. DOI: <http://dx.doi.org/10.1787/9789264071148-en>
- OECD (2006) Test No. 435: In Vitro Membrane Barrier Test Method for Skin Corrosion, OECD Publishing, Paris. DOI: <http://dx.doi.org/10.1787/9789264067318-en>
- OECD (2010) Test No. 439: In Vitro Skin Irritation: Reconstructed Human Epidermis Test Method, OECD Publishing, Paris. DOI: <http://dx.doi.org/10.1787/9789264090958-en>
- Ottaviani G, Martel S, Carrupt P-A (2006) Parallel artificial membrane permeability assay: a new membrane for the fast prediction of passive human skin permeability. *J Med Chem* 49:3948–3954
- Patzelt A, Richter H, Knorr F, Schaefer U, Lehr C-M, Dähne L et al (2011) Selective follicular targeting by modification of the particle sizes. *J Control Release* 150:45–48
- Pittermann WF, Kietzmann M (2006) Bovine Udder Skin (BUS): testing of skin compatibility and skin protection. *Bovine Udder Skin (BUS): Prüfung von Hautverträglichkeit und Hautschutz* 23:65–71
- Poet TS, McDougal JN (2002) Skin absorption and human risk assessment. *Chem Biol Interact* 140:19–34
- Prow TW, Grice JE, Lin LL, Faye R, Butler M, Becker W et al (2011) Nanoparticles and microparticles for skin drug delivery. *Adv Drug Deliv Rev* 63:470–491
- Rauma M, Boman A, Johanson G (2013) Predicting the absorption of chemical vapours. *Adv Drug Deliv Rev* 65:306–314
- Reichling J, Landvatter U, Wagner H, Kostka KH, Schaefer UF (2006) In vitro studies on release and human skin permeation of Australian tea tree oil (TTO) from topical formulations. *Eur J Pharm Biopharm* 64:222–228
- Roberts M, Cross S, Pellett M (2002) Skin transport. In: Walters K (ed) *Dermatological and transdermal formulations*, vol 119. Marcel Dekker, New York, pp 89–195
- Rossignol MR (2005) The 7th Amendment to the Cosmetics Directive. *Atla-Altern Lab Anim* 33:19–22
- Russell LM, Guy RH (2012) Novel imaging method to quantify stratum corneum in dermatopharmacokinetic studies. *Pharma Res* 29:2389–2397
- Russell C, Russell WMS (1957) An approach to human ethology. *Behav Sci* 2:169–200
- Russell LM, Wiedersberg S, Begoña Delgado-Charro M (2008) The determination of stratum corneum thickness. An alternative approach. *Eur J Pharm Biopharm* 69:861–870
- Savic S, Weber C, Tamburic S, Savic M, Müller-Goymann C (2009) Topical vehicles based on natural surfactant/fatty alcohols mixed emulsifier: the influence of two polyols on the colloidal structure and in vitro/in vivo skin performance. *J Pharm Sci* 98:2073–2090
- SCCNFP/0167/99, (2003), Final: Basic Criteria for the in vitro assessment of percutaneous absorption of cosmetic ingredients, adopted by the SCCNFP during the 8th plenary meeting of 23 June 1999. European Commission Health & Consumers, Directorate C: Public Health and Risk Assessment, Unit C7 - Risk Assessment Office: B232 B-1049, Brussels, Belgium
- SCCNFP/0690/03 (2003) Final: Notes of Guidance for Testing of Cosmetic Ingredients for Their Safety Evaluation, adopted by the SCCNFP during the 25th plenary meeting of 20 October 2003. European Commission Health & Consumers, Directorate C: Public Health and Risk Assessment, Unit C7 - Risk Assessment Office: B232 B-1049, Brussels, Belgium
- SCCS/1358/10 (2010) Basic criteria for the in vitro assessment of dermal absorption of cosmetic ingredients, doi: 10.2772/25843, European Commission, Health & Consumers Directorate C: Public Health and Risk Assessment, Unit C7 - Risk Assessment, Office: B232 B-1049 Brussels, Belgium, doi: 10.2772/25843
- Schaefer H, Loth H (1996) An ex vivo model for the study of drug penetration into human skin. *Pharm Res* 13:366
- Schaefer U, Hansen S, Schneider M, Luengo J, Lehr C-M (2008) Models for skin absorption and skin toxicity testing. *Drug absorption studies: in situ, in vitro and in silico models*. Springer, New York
- Schäfer-Korting M, Bock U, Gamer A, Haberland A, Haltner-Ukomadu E, Kaca M et al (2006) Reconstructed human epidermis for skin absorption testing: results of the German prevalidation study. *ATLA Altern Lab Anim* 34:283–294
- Schäfer-Korting M, Bock U, Diembeck W, Düsing HJ, Gamer A, Haltner-Ukomadu E et al (2008) The use of reconstructed human epidermis for skin absorption testing: results of the validation study. *ATLA Altern Lab Anim* 36:161–187
- Schreiber S, Mahmoud A, Vuia A, Rübhelke MK, Schmidt E, Schaller M et al (2005) Reconstructed epidermis versus human and animal skin in skin absorption studies. *Toxicol In Vitro* 19:813–822
- Sclafani J, Liu P, Hansen E, Cettina MG, Nightingale J (1995) A protocol for the assessment of receiver solution additive-induced skin permeability changes. An example with  $\gamma$ -cyclodextrin. *Int J Pharm* 124:213–217
- Scott RC, Walker M, Dugard PH (1986) In vitro percutaneous absorption experiments: a technique for the production of intact epidermal membranes from rat skin. *J Soc Cosm Chem Jap* 37:35–41
- Selzer D, Schaefer UF, Lehr C-M, Hansen S (2013) Basic mathematics in skin absorption. In: Dragicevic-Curic

- N, Maibach HI (eds) Chemical methods in penetration enhancement. Springer, Heidelberg
- Semlin L, Schäfer-Korting M, Borelli C, Korting HC (2011) In vitro models for human skin disease. *Drug Discov Today* 16:132–139
- Shah VP, Flynn GL, Yacobi A, Maibach HI, Bon C, Fleischer NM et al (1998) Bioequivalence of topical dermatological dosage forms – methods of evaluation of bioequivalence. *Pharm Res* 15:167–171
- Sinkó B, Garrigues TM, Balogh GT, Nagy ZK, Tsinman O, Avdeef A et al (2012) Skin-PAMPA: a new method for fast prediction of skin penetration. *Eur J Pharm Sci* 45:698–707
- Solich P, Ogrocka E, Schaefer U (2001) Application of automated flow injection analysis to drug liberations studies with the Franz diffusion cell. *Die Pharmazie* 56:787–789
- Solich P, Sklenarova H, Huclova J, Stafinsky D, Schaefer UF (2003) Fully automated drug liberation apparatus for semisolid preparations based on sequential injection analysis. *Anal Chim Acta* 499:9–16
- Spielmann H, Müller L, Averbek D, Balls M, Brendler-Schwaab S, Castell JV et al (2000) The second ECVAM workshop on phototoxicity testing: the report and recommendations of ECVAM workshop 42 1,2. *ATLA Altern Lab Anim* 28:777–814
- Surber C, Smith EW (2005) The mystical effects of dermatological vehicles. *Dermatology* 210:157–168
- Surber C, Schwarb FP, Smith EW (1999) Tape-stripping technique. In: Bronaugh RL, Maibach H (eds) *Percutaneous absorption: drugs-cosmetics-mechanisms-methodology*, vol 97, 3rd ed. Marcel Dekker, New York, pp 395–409
- Swarbrick J, Lee G, Brom J (1982) Drug permeation through human skin: I. Effect of storage conditions of skin. *J Invest Dermatol* 78:63–66
- USEPA (2004) In vitro dermal absorption rate testing of certain chemicals of interest to the Occupational Safety and Health Administration; Final rule. *Fed Regist*; 69(80):22402–41. <https://www.gpo.gov/fdsys/pkg/FR-2004-04-26/pdf/04-9409.pdf>
- Van De Sandt JJM, Meuling WJA, Elliott GR, Cnubben NHP, Hakkert BC (2000) Comparative in vitro-in vivo percutaneous absorption of the pesticide propoxur. *Toxicol Sci* 58:15–22
- van de Sandt JJM, van Burgsteden JA, Cage S, Carmichael PL, Dick I, Kenyon S et al (2004) In vitro predictions of skin absorption of caffeine, testosterone, and benzoic acid: a multi-centre comparison study. *Regul Toxicol Pharmacol* 39:271–281
- Veccia BE, Bunge AL (2003) Skin absorption databases and predictive equations. In: Guy R, Hadgraft J (eds) *Transdermal drug delivery*, vol 123, 2nd ed. Marcel Dekker, New York, pp 57–141
- Voegeli R, Heiland J, Doppler S, Rawlings AV, Schreier T (2007) Efficient and simple quantification of stratum corneum proteins on tape strippings by infrared densitometry. *Skin Res Technol* 13:242–251
- Wagner H, Kostka KH, Lehr CM, Schaefer UF (2000) Drug distribution in human skin using two different in vitro test systems: comparison with in vivo data. *Pharm Res* 17:1475–1481
- Wagner H, Kostka KH, Lehr CM, Schaefer UF (2001) Interrelation of permeation and penetration parameters obtained from in vitro experiments with human skin and skin equivalents. *J Control Release* 75:283–295
- Wagner H, Kostka KH, Lehr CM, Schaefer UF (2002) Correlation between stratum corneum/water-partition coefficient and amounts of flufenamic acid penetrated into the stratum corneum. *J Pharm Sci* 91:1915–1921
- Weigmann HJ, Lindemann U, Antoniou C, Tsirikas GN, Stratigos AI, Katsambas A et al (2003) UV/VIS absorbance allows rapid, accurate, and reproducible mass determination of corneocytes removed by tape stripping. *Skin Pharmacol Appl Skin Physiol* 16:217–227
- Wertz PW (1996) The nature of the epidermal barrier: biochemical aspects. *Adv Drug Deliv Rev* 18:283–294
- WHO (2006) *Dermal Absorption*. Environmental Health Criteria (EHC) 235, ISBN 978 92-4-157235, World Health Organization, Geneva
- Wilkinson SC, Mass WJM, Nielsen JB, Greaves LC, van de Sandt JJM, Williams FM (2004) Influence of skin thickness on percutaneous penetration in vitro. In: Brain KR, Walters KA (eds) *Perspectives in percutaneous penetration*, vol 9a. STS Publishing, Cardiff
- Wilkinson SC, Maas WJM, Nielsen JB, Greaves LC, van de Sandt JJM, Williams FM (2006) Interactions of skin thickness and physicochemical properties of test compounds in percutaneous penetration studies. In *Arch Occup Environ Health* 79:405–413
- Williams AC, Barry BW (2012) Penetration enhancers. *Adv Drug Deliv Rev* 64(Suppl):128–137